搜索:   联系我们 |  English 


    发布时间:2017-06-05 16:03:25    点击:1155

学术报告


报告题目:Bioengineering of Direct Cellular Reprogramming
报 告 人:Kam W Leong, Samuel Y Sheng Professor
          Department of Biomedical Engineering | Department of Systems Biology
          Columbia University | New York, NY 10027
Email: kam.leong@columbia.edu
时 间: 2017年6月09日(周五)上午 10:00
地 点: 仙林校区化学楼H-201
 
Abstract: Direct cell reprogramming or transdifferentiation, where adult cells are reprogrammed from one lineage to another without going through an intermediate stem cell-like stage, produces cells promising for regenerative medicine. It obviates the use of embryos and minimizes the risk of teratoma formation associated with the in vivo application of induced pluripotent stem cells. Direct reprogramming can also produce cells for disease modeling and drug screening. I will discuss our recent effort to convert human endothelial progenitors (hEPC) into induced smooth muscle cells (iSMC), hEPC into induced skeletal myocytes (iSkM), human fibroblasts into induced cardiomyocyte-like cells (iSML), and murine fibroblasts into induced neurons (iN). I will describe various approaches of achieving direct cell reprogramming using transcription factor overexpression, microRNA delivery, molecular pathway manipulation, and CRISPR/dCas9-based transactivation either separately or in combination. This will be presented from the perspective of how biomaterials and biomedical engineering researchers can help advance this exciting field.
 
Biography: Kam W. Leong is the Samuel Y. Sheng Professor of Biomedical Engineering at Columbia University. He is the Editor-in-Chief of Biomaterials, a member of the USA National Academy of Inventors, and a member of the USA National Academy of Engineering. He received his PhD in Chemical Engineering from the University of Pennsylvania. After serving as a faculty in the Department of Biomedical Engineering at The Johns Hopkins School of Medicine for almost 20 years, he moved to Duke University in 2006 to study the interactions of cells with nanostructures for therapeutic applications. After moving to Columbia University in September 2014, he continues to work on nanoparticle-mediated nonviral gene delivery and immunotherapy. The lab also works on the application of nanostructured biomaterials for regenerative medicine, particularly on understanding cell-topography interactions and on the application of nonviral vectors for direct cellular reprogramming and genome editing. He has published ~330 peer-reviewed research manuscripts with >35,000 citations, and holds more than 50 issued patents. His work has been recognized by a Young Investigator Research Achievement Award of the Controlled Release Society, Distinguished Scientist Award of the International Journal of Nanomedicine, Clemson Award for Applied Research of the Society for Biomaterials, and Life Time Achievement Award of the Chinese American Society of Nanomedicine and Nanotechnology.
 
生命分析化学国家重点实验室
南京大学化学化工学院

地址:江苏省南京市栖霞区仙林大道163号南京大学化学楼    邮编:210023    电话:86-25-89682304   传真:86-25-89687761

© 2010-2017   南京大学 化学化工学院